$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
坦罗莫司打几次有效果?
2025-10-19 11:44:20
Check Details
坦罗莫司多久打一次?
2025-10-19 11:44:20
Check Details
卡博替尼(XL184)可有效改善晚期肾脏癌患者生存期
2025-10-19 11:44:20
Check Details
新发现!转移性肾癌患者应考虑基线脑成像
2025-10-19 11:44:20
Check Details
卡博替尼(XL184)在转移性肾细胞癌患者中的效果数据
2025-10-19 11:44:20
Check Details
卡博替尼(Cabozantinib)可延长患者生存期
2025-10-19 11:44:20
Check Details
卡博替尼(Cabozantinib)的安全性和耐受性及不良反应
2025-10-19 11:44:20
Check Details
2021年索坦报销后多少钱一盒
2025-10-19 11:44:20
Check Details
晚期肾癌吃索坦效果怎么样
2025-10-19 11:44:20
Check Details
如何分辨索坦和多吉美的区别
2025-10-19 11:44:20
Check Details
靶向药索拉非尼片中途停药会怎样
2025-10-19 11:44:20
Check Details
舒尼替尼(索坦)服用方法|剂量调整|副作用处理方法
2025-10-19 11:44:20
Check Details
1
2
...
2381
2382
2383
2384
2385
2386
2387
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
2
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
3
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
4
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
5
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
6
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
7
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
8
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
9
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
10
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
11
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
12
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice